Trial tests adult stems cells to treat congestive heart failure
Some individuals would rather receive clear negative information than deal with ambiguity or uncertainty, according to new research out of the University of Toronto. In a new study published in Psychological Science, U of T researchers examined whether people reacted more strongly to negative or to uncertain feedback. Participants’ brain activity was measured as they
Full Post: Neurotic individuals more comfortable with clear negative information than uncertainty
The University of California, San Diego Medical Center is the first hospital in California to enroll patients in a multi-center clinical trial, sponsored by Angioblast Systems Inc., to examine the safety and feasibility of administering adult stems cells to treat congestive heart failure.
The cells, derived from bone marrow, are injected by a catheter directly into the heart muscle. Sixty patients will be recruited for this clinical trial through UC San Diego Medical Center and hospitals nationwide.
“This Phase 2 clinical trial will evaluate whether or not adult stems cells can be targeted to the heart muscle to repair and help improve cardiac function in patients with severe heart disease,” said Anthony DeMaria, M.D., director of the Sulpizio Family Cardiovascular Center at UC San Diego Medical Center. “The hope is to identify an effective, minimally-invasive treatment for the growing numbers of patients in the U.S. who suffer from advanced heart failure and have no other treatment alternatives.”
Heart failure, which affects more than five million patients in the United States, is a condition in which the heart progressively loses its ability to pump blood throughout the body. Heart failure patients often have a history of prior heart attack and underlying disorders such as narrowing and hardening of the arteries, high blood pressure, and arrhythmia or irregular heartbeat.
The stem cells used in this clinical trial are derived from the bone marrow of an adult donor. Angioblast Systems Inc. of New York has identified a population of stem cells which may stimulate the regrowth of a patient’s own heart muscle cells and blood vessels. This cell type is selected and prepared from a universal donor, expanded into large numbers, and injected into a recipient. The cells can be used in unrelated recipients because they do not activate the immune system.
Before the cells are injected into the patient’s heart, a three-dimensional color-coded map is made of the heart’s left ventricle, where the pumping action takes place. Using a technology called the NOGA XP Cardiac Navigation System, a visual is created which identifies the electric signals of the heart. By assessing the living and scarred areas, physicians can identify diseased tissue and then guide the injection catheter with pinpoint accuracy to the desired location.
Upon completion of the map, the patient undergoes a one-hour procedure in which a long catheter, a thin tube, is threaded through the femoral artery in the leg and then up into the heart. This procedure, performed by Nabil Dib, M.D., associate professor and co-investigator of the trial, uses a series of tiny needle injections to deliver millions of cells to the areas of the heart surrounding the scar tissue.
“The concept is that the adult stem cells will either directly or indirectly rebuild the patient’s blood vessels and damaged heart muscle,” said DeMaria, principal investigator of the trial. “What we would like to see in six months is that the heart will have more exertional capacity, and increased contractility, and blood flow. Only through testing will we know for certain.”
This is a randomized, placebo-controlled clinical trial. Three out of four patients in the trial will receive the adult stem cells in different doses. Patients who are eligible for the trial must have symptoms of heart failure, such as shortness of breath, and be ineligible for any other form of medical or surgical therapy.
All patients are followed for a period of one year following the procedure. Exercise tests, echocardiograms, and blood tests will be performed periodically to evaluate changes in the heart’s function. At the conclusion of a three-year period, patients will be informed as to whether or not they received the stem cell treatment.
Ron Ferstadt, 71, of Los Angeles is one of the first patients to enroll in the clinical trial. After suffering four heart attacks, he is looking to new frontiers in science to offer a possible improvement in his heart’s function.
“I waited two years to participate in a study like this one. It’s worth a try,” said Ferstadt, a retired machinist and former competitive ballroom dancer. “The world of medicine will change dramatically in the next decade. I may or may not see it, but it is studies like this that will help offer new treatments.”
Members of the clinical trial team include: Nabil Dib, M.D., Ehtisham Mahmud, M.D., Bruno Cotter, M.D., Kendra Bartels, R.N. and Muppy Haigler, N.P.
Patients who would like to inquire about enrolling in this clinical trial may call 619-543-3343.
Researchers at the University of Utah are enrolling people in a new clinical trial that uses a patient’s own stem cells to treat ischemic and non-ischemic heart failure. The one-year Cardiac Repair Cell Treatment of Patients with Dilated Cardiomyopathy (IMPACT-DCM) study will look at the safety of injecting Cardiac Repair Cells (CRC) and their ability
Full Post: Scientists use patient’s own stem cells to treat heart failure
UC San Diego Medical Center is currently enrolling patients in a Phase 2 clinical trial of an investigational drug for the treatment of advanced heart failure. The “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease,” or CUPID, study is evaluating a new gene-based therapy designed to stimulate production of an enzyme that
Full Post: Trial of investigational drug for treatment of advanced heart failure
Researchers at Children’s Hospital of Pittsburgh of UPMC have been able to effectively repair damaged heart muscle in an animal model using a novel population of stem cells they discovered that is derived from human skeletal muscle tissue. The research team - led by Johnny Huard, PhD - transplanted stem cells purified from human muscle-derived
Full Post: Researchers repair injured heart muscle with novel stem cells
Up until today scientists assumed that the adult heart is unable to regenerate. Now, researchers and cardiologists from the Max Delbr?nter for Molecular Medicine (MDC) Berlin-Buch and the Charité - Universit?medizin Berlin (Germany) have been able to show that this dogma no longer holds true. Dr. Laura Zelarayán and Assistant Professor Dr. Martin W. Bergmann
Full Post: Heart regenerates after infarction
Individuals who have persistent high blood pressure are at increased risks of a number of serious medical conditions, including heart failure. One of the factors that contributes to such heart failure is thickening of the muscle wall of the heart. Such thickening (known as hypertrophy) is a compensatory response of the heart to the high
Full Post: Molecular insight into how a heart failure drug in clinical trials works